MiMedx Group Inc
MDXG
NASDAQ
Biotechnology
$4.27
USD
+0.07 (+1.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $612.19M
Volume 974.8K
About MiMedx Group Inc
The company is headquartered in Marietta, Georgia and currently employs 808 full-time employees. The company went IPO on 2007-08-20.
CEO
Mr. Joseph Capper
HQ
Marietta, GEORGIA, US
Founded
2007
Employees
808
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
7 metrics our research team weighs before forming a view on MDXG.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-2.4%
-9.2 pp
Gross Margin (TTM)
78.8%
-2.6 pp
Operating Margin (TTM)
2.5%
-9.4 pp
Net Margin (TTM)
1.8%
-7.0 pp
ROE (TTM)
2.9%
-11.9 pp
EPS Growth (TTM)
-31.2%
+42.5 pp
Free Cash Flow (TTM)
$44.50M
-22.1%
Financial Snapshot
Revenue
$355.17M
-2.4%
YoY
Gross Margin
79%
TTM
-3.2%
YoY
Net Income
$6.24M
-80.5%
YoY
Operating Cash Flow
$46.15M
-20.6%
YoY
Key Statistics
Open
$4.19
Previous Close
$4.20
Day Range
$4.12 - $4.32
52 Week Range
$3.03 - $7.97
Volume
974.8K
Average Volume (10 Days)
2.0M
Dividend Yield
—
Valuation Measurement
Market Cap
$612.19M
P/E Ratio (TTM)
98.12
P/S Ratio (TTM)
1.72
Price / Book
2.83
Financial Highlights
Profit Margin
1.8%
Return on Assets
2.2%
Return on Equity
2.9%
Revenue (TTM)
$355.17M
Net Income (TTM)
$6.24M
Diluted EPS (TTM)
$0.11
Total Cash (MRQ)
$135.84M
Levered FCF (TTM)
$44.50M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
SGMT
Sagimet Biosciences Inc
$10.55
▲ +13.7%
EIKN
Eikon Therapeutics Inc
$11.05
▲ +7.0%
ARTV
Artiva Biotherapeutics Inc
$11.45
▲ +1.3%
CBIO
Crescent Biopharma Inc
$17.14
▲ +3.1%
FDMT
4D Molecular Therapeutics Inc
$12.19
▲ +4.6%
PRME
Prime Medicine Inc
$3.09
▼ -2.5%
ALT
Altimmune Inc
$2.94
▲ +2.1%
NVCT
Nuvectis Pharma Inc
$18.96
▼ -1.4%
SPRY
ARS Pharmaceuticals Inc
$5.65
▼ -7.4%
ASMB
Assembly Biosciences Inc
$32.95
▲ +10.0%
Earnings Calendar
Next Earnings
Estimated Q3 Release
Oct 27
Est. EPS
Adjusted consensus estimate
-$0.02